No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
EDSA Edesa Biotech
- 4.5714
- +0.0214+0.47%
Close May 22 16:00 ET
- 4.7000
- +0.1286+2.81%
Post 17:36 ET
14.70MMarket Cap-1945P/E (TTM)
4.6440High4.5000Low7.99KVolume4.6000Open4.5500Pre Close36.08KTurnover0.34%Turnover RatioLossP/E (Static)3.22MShares8.333052wk High3.40P/B10.81MFloat Cap2.460052wk Low--Dividend TTM2.36MShs Float461.1600Historical High--Div YieldTTM3.17%Amplitude2.4600Historical Low4.5150Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Edesa Biotech | 10-Q: Quarterly report
Edesa Biotech Advances Clinical Trials, Manages Finances
Express News | Edesa Biotech Q2 EPS $(0.58) Beats $(0.69) Estimate
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disease
Edesa Biotech Showcases Innovation at Investor Conference
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
TORONTO, ON / ACCESSWIRE / April 11, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disea
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg